The biopharmaceutical company secures $150 million through a share sale to fund operations and pipeline development.
InflaRx has priced a $150 million offering of ordinary shares, aiming to bolster its financial position. The proceeds will support ongoing research, clinical trials, and commercialization efforts for its drug candidates.
The company had not previously disclosed the size of this offering, though it has conducted smaller financings in the past. This move follows recent advancements in its pipeline, including progress in late-stage clinical programs.
Shares of InflaRx may experience volatility as investors assess the dilution impact and long-term strategic benefits of the capital raise.